Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor sasanlimab in patients with BCG-naïve, high-risk, non-muscle invasive ...

Pfizer has reported positive outcomes from ... Earlier this month, the company’s CREST trial assessing sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or without ...

Pfizer also has high hopes for PD-1/PD-L1 inhibitor sasanlimab for non-muscle invasive bladder cancer in the CREST study, and CD3xBCMA bispecific Elrexfio (elranatamab) in MagnetisMM-5 as a ...

Pfizer's EPS and revenue beat my expectations ... From the list of its product candidates, which you can also see below, I highlight sasanlimab [bladder cancer], atirmociclib [breast cancer ...